<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03482167</url>
  </required_header>
  <id_info>
    <org_study_id>1079271</org_study_id>
    <secondary_id>K01AG054731</secondary_id>
    <nct_id>NCT03482167</nct_id>
  </id_info>
  <brief_title>NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment</brief_title>
  <official_title>NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Delaware</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Delaware</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will provide insight into whether a nutritional supplement, nicotinamide riboside
      (NR), improves memory and brain blood flow in older adults with low memory abilities.
      Overall, this project has the potential to identify a novel, safe and cost-effective strategy
      for decreasing age-related memory loss.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in cognitive scores at 12 weeks</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>change in one or more domains of cognitive function including: episodic memory, attention, working memory, processing speed, executive function and language abilities from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cerebrovascular reactivity at 12 weeks</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Cerebrovascular reactivity to hypercapnia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total brain blood flow at 12 weeks</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Total brain blood flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in aortic stiffness at 12 weeks</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Carotid-femoral pulse wave velocity (CFPWV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood pressure at 12 weeks</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in neurovascular coupling at 12 weeks</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Cerebrovascular reactivity to cognitive tasks</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in functional brain connectivity at 12 weeks</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>functional brain connectivity assessed by MRI</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in neuronal activation at 12 weeks</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Functional MRI (fMRI) to cognitive task</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in brain volume at 12 weeks</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>White and grey matter volume assessed by structural MRI</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotinamide Riboside</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Niagen® (ChromaDex, Inc.) 500 mg, twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niagen®</intervention_name>
    <description>250 mg capsules (4 capsules daily)</description>
    <arm_group_label>Nicotinamide Riboside</arm_group_label>
    <other_name>nicotinamide riboside chloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Cognitive function scores consistent with amnestic mild cognitive impairment based on
             pre-screening evaluation;

          -  age 60-90 years;

          -  MMSE score &gt;24 at time of initial consent;

        Exclusion Criteria

          -  blood chemistries indicative of abnormal renal, liver, thyroid and adrenal function;
             estimated glomerular filtration rate using the MDRD prediction equation must be &gt;30
             ml/min/1.73 m2;

          -  any clinically significant abnormal blood chemistry values as determined by the
             research nurse or NMPCC nurse practitioner;

          -  major psychiatric disorder (e.g. schizophrenia, bipolar disorder, major depression
             within past two years);

          -  neurological or autoimmune conditions affecting cognition (e.g. Parkinson's disease,
             epilepsy, multiple sclerosis, mild or severe traumatic brain injury, large vessel
             infarct);

          -  concussion within last 2 years and ≥ 3 lifetime concussions;

          -  systemic medical illnesses (e.g. cardiovascular disease, cancer, renal failure);

          -  substance abuse or dependence (DSM-V criteria);

          -  current use of medications used to treat dementia (e.g., anticholinesterase drugs) or
             other drugs likely to affect cognition (e.g., anticholinergic drugs, long-acting
             benzodiazepines);

          -  claustrophobia, metal implants, pacemaker or other factors affecting feasibility
             and/or safety of MRI scanning*;

          -  current smoking (including marijuana) within the past 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher R Martens, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Delaware</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joshua Hobson, M.S.</last_name>
    <phone>302-831-8137</phone>
    <email>chs-novalab@udel.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neurovascular Aging Laboratory</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Hobson, MS</last_name>
      <phone>302-831-8137</phone>
      <email>chs-novalab@udel.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher R Martens, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 14, 2018</study_first_submitted>
  <study_first_submitted_qc>March 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Delaware</investigator_affiliation>
    <investigator_full_name>Christopher Martens</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>blood pressure</keyword>
  <keyword>arterial stiffness</keyword>
  <keyword>cerebrovascular function</keyword>
  <keyword>cognitive function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

